Lexington, Mass., USA - March 31, 2016, Lexington, Mass., USA - Curis, Inc., a biotechnology company, announced the appointment of James E. Dentzer as chief financial and chief administrative officer.
Article continues below
Mr. Dentzer most recently served as Chief Financial Officer of Dicerna Pharmaceuticals, where he led successful IPO and follow-on financings, and helped establish the company as a leader in RNAi therapeutics.
Previously, Mr. Dentzer helped finance and develop global biotechnology organizations as Chief Financial Officer at Valeritas, Inc. and Amicus Therapeutics, Inc., and Vice President and Corporate Controller of Biogen.
Prior to Biogen, he held roles of increasing responsibility at DuPont, Kemper Financial Services, and Bank of America (formerly Bank of Boston).
Mr. Dentzer holds a B.A. from Boston College and an M.B.A. from the University of Chicago.
The company also announced the promotions of David Tuck to the role of Chief Medical Officer, and Mani Mohindru to the role of Chief Strategy Officer.
Dr. Tuck joined Curis in May 2015 and has most recently served as the Company's Senior Vice President of Clinical and Translational Sciences. He joined Curis from EMD Serono, where he served as Senior Medical Director in the Oncology Translational Innovation program.
Previously, Dr. Tuck was at Bristol-Myers Squibb Global Oncology Research in the role of Translational Physician for ipilimumab, with a primary focus on external development of immune checkpoint inhibitors in solid tumors and hematological malignancies.
He was an Associate Professor at Yale University and Associate Director of the Yale Cancer Center.
Dr. Tuck earned his Medical Degree at the University of Vermont School of Medicine and is board certified in internal medicine, medical oncology and hematology.
Dr. Mohindru joined Curis in June 2013 and has most recently served as the Company's Senior Vice President of Corporate Strategy and Investor Relations.
Previously, she spent several years as a Wall Street equity research analyst covering the biotechnology sector, including analyst roles at ThinkEquity LLC, Credit Suisse Securities and UBS Securities.
Dr. Mohindru was a healthcare industry consultant at Axon Healthcare Partners and SAI Healthcare (acquired by IMS Health), and also a Managing Director in healthcare investment banking at Capstone Investments. ■